Outcomes of Australian patients receiving non ‐funded anti‐PD‐1 immune checkpoint inhibitors for non‐melanoma cancers

ConclusionThe response rates and overall survival of patients with NSCLC, renal carcinoma and triple negative breast cancer of good performance status receiving anti‐PD‐1 therapy outside of a clinical trial are consistent with clinical trial data. However, patients with poor ECOG performance status are unlikely to respond. Careful patient selection and counseling about the potential outcomes of self‐funding treatment in this setting is needed.

Source: Asia-Pacific Journal of Clinical Oncology - March 1, 2018 Category: Cancer & Oncology Authors: Crescens Tiu, Annie Wong, Alan Herschtal, Linda Mileshkin Tags: ORIGINAL ARTICLE Source Type: research